HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 26322580)

Published in Nat Med on August 31, 2015

Authors

Holly Janes1, Joshua T Herbeck2, Sodsai Tovanabutra3,4, Rasmi Thomas3,4, Nicole Frahm1,2, Ann Duerr1, John Hural1, Lawrence Corey1, Steve G Self1, Susan P Buchbinder1, M Juliana McElrath1,2,5,6, Robert J O'Connell7, Robert M Paris3, Supachai Rerks-Ngarm8, Sorachai Nitayaphan7, Punnee Pitisuttihum9, Jaranit Kaewkungwal9, Merlin L Robb3,4, Nelson L Michael3, James I Mullins10, Jerome H Kim3, Peter B Gilbert1, Morgane Rolland3,4

Author Affiliations

1: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
2: Department of Global Health, University of Washington, Seattle, Washington, USA.
3: US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
4: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
5: Department of Medicine, University of Washington, Seattle, Washington, USA.
6: Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
7: Royal Thai Army Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
8: Thai Ministry of Public Health, Nonthaburi, Thailand.
9: Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
10: Department of Microbiology, University of Washington, Seattle, Washington, USA.

Associated clinical trials:

HIV Vaccine Trial in Thai Adults | NCT00223080

Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) | NCT00095576

Articles cited by this

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44

Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14

Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40

HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71

Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48

Dual HIV-1 infection associated with rapid disease progression. Lancet (2004) 2.17

Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol (2003) 1.96

Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis (2011) 1.84

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis (2012) 1.65

Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog (2010) 1.63

Sieve analysis in HIV-1 vaccine efficacy trials. Curr Opin HIV AIDS (2013) 1.07

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One (2012) 1.03

The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog (2014) 0.97

HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics (2014) 0.90

Articles by these authors

COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol (2015) 1.14

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. J Virol (2014) 1.03

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med (2016) 0.98

Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol (2014) 0.96

Dendritic cells restore CD8+ T cell reactivity to autologous HIV-1. J Virol (2014) 0.82

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees. PLoS Comput Biol (2015) 0.80

Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults. Clin Vaccine Immunol (2016) 0.76

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog (2017) 0.76

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. PLoS One (2014) 0.75

Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells. MBio (2016) 0.75

Erratum for Smith et al., Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells. MBio (2016) 0.75

Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. J Exp Med (2017) 0.75

DNA priming increases frequency of T-cell responses to a VSV HIV vaccine with specific enhancement of CD8(+) T-cell responses by IL-12 pDNA. Clin Vaccine Immunol (2017) 0.75

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Stat Commun Infect Dis (2017) 0.75

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. Sci Rep (2017) 0.75

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med (2017) 0.75